Fundamental Pharma

FundaMental Pharma is engaged in pioneering research on a novel type of dual-acting modulators of the N-methyl-D-aspartate receptor (NMDAR) for treatment-resistant depression (TRD): • NMDAR/TRPM4 complex disruption modulates extrasynaptic NMDAR signaling, thereby boosting antidepressant efficacy and providing neuroprotection • NMDAR antagonism represents a clinically validated antidepressive mechanism of action with rapid onset and substantial efficacy in TRD patients FundaMental Pharma’s clinical candidate FMP374 is a dual-acting molecule with a higher affinity for the NMDA receptor than the current standard of care esketamine and is orally bioavailable. Our preclinical data highlight the extraordinary profile of FMP374 which will be developed as a fast-acting, non-dissociating / non-hallucinogenic at home treatment for treatment-resistant depression.